Skip to ContentSkip to Navigation
Practical matters How to find us dr. B. Gareb


Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease

Targeting the ileo-colonic region in inflammatory bowel disease

De ontwikkeling van budesonidetabletten met nulde-orde-afgifte voor de behandeling van ileo-colonische inflammatoire darmziekten en vergelijking met huidige, commerciële preparaten

Review: Local Tumor Necrosis Factor-alpha Inhibition in Inflammatory Bowel Disease

Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice

Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process

Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease

Read more